SCHEMBL3478296

SCHEMBL3478296

Cc1cccc(S(=O)(=O)C2CCN(C(=O)c3cccc(N4CCN(C)CC4)n3)CC2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B14 Q9BPX1 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ PRKCQ Q04759 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HTR2A P28223 1/20 0.40
▸ HTR2C P28335 1/20 0.40
▸ HTR3E A5X5Y0 3/20 0.40
▸ HTR3B O95264 3/20 0.40
▸ HTR3A P46098 3/20 0.40
▸ HTR3D Q70Z44 3/20 0.40
▸ HTR3C Q8WXA8 3/20 0.40
▸ AKR1C3 P42330 1/20 0.39
▸ HTR6 P50406 1/20 0.39
▸ RAD52 P43351 1/20 0.38
▸ SPR P35270 1/20 0.38
▸ GBA1 P04062 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HSD11B1 P28845 1/20 0.37
▸ KDM2B Q8NHM5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4290842 0.76 HSD17B14 (0.46) HSD17B14HPGDPRKCQHTR3EHTR3B
SCHEMBL1806706 0.76 SPR (0.45) HSD17B14SPRGBA1HSD11B1
SCHEMBL23799261 0.75 SPR (0.46) KMT2AHTR2AHTR2CAKR1C3SPR
SCHEMBL3470360 0.73 HSD17B14 (0.48) HSD17B14PRKCQHTR3EHTR3BHTR3A
SCHEMBL3469979 0.73 USP2 (0.52) HSD17B14PRKCQKMT2AHTR3EHTR3B
SCHEMBL4299601 0.73 PRKCQ (0.44) HSD17B14PRKCQKDM4EALDH1A1
SCHEMBL4299606 0.73 PRKCQ (0.44) HSD17B14PRKCQKDM4EALDH1A1
SCHEMBL7890738 0.73 PRKCQ (0.44) HSD17B14PRKCQKDM4EALDH1A1
SCHEMBL3466177 0.73 HSD17B14 (0.49) HSD17B14PRKCQKMT2AHTR3EHTR3B
SCHEMBL3469936 0.72 HSD17B14 (0.47) HSD17B14PRKCQHTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265600-A1 PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS Pfizer Inc. (US) 2010-12-29 — — EP disclosed
WO-2009098576-A1 PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS PFIZER INC. (US) 2009-08-13 — — WO disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders HTR6, HTR5A, TPH1 HSD17B14 2214/4885HPGD 1395/4885PRKCQ 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback